Variants in SCN1A, the gene encoding the neuronal voltage-gated sodium channel NaV1.1, are the most common genetic cause of epilepsy. Historically, loss-of-function SCN1A variants underlie Dravet syndrome, presenting with temperature-sensitive seizures beginning in infancy, developmental impairment, and autism features. In contrast, an emerging set of patient variants produce gain-of-function (GoF) effects on NaV1.1 and are associated with a distinct clinical picture: earlier seizure onset, prominent movement disorder, and lack of temperature sensitivity. The cellular and circuit mechanisms driving disease in SCN1A GoF remain incompletely understood.
To address this gap, the authors created a genetic, cell type–controllable mouse model expressing a recurrent patient variant, Scn1a-p.R1636Q, to study in vivo consequences of NaV1.1 GoF on neuronal populations, seizure propensity, and survival.
The investigators developed the first heterozygous, Cre-dependent knock-in allele encoding the recurrent GoF variant Scn1a-p.R1636Q. This floxed allele permits selective activation of the mutant NaV1.1 in defined cell populations using Cre driver lines. The design enables comparison of effects of global activation versus activation restricted to specific neuronal subclasses, facilitating dissection of the cell types responsible for disease phenotypes.
When the mutant allele was expressed globally, all mutant mice (64 of 64 reported) experienced spontaneous, convulsive seizures and showed premature mortality between postnatal day 12 and 18. The authors attribute death to seizure-related causes. These findings establish that heterozygous expression of this GoF SCN1A variant is sufficient to produce an early, severe epilepsy phenotype in mice.
Using Cre drivers to restrict expression of Scn1a-p.R1636Q to specific neuronal classes, the authors examined which cell types recapitulate the global phenotype. Activation of the mutant allele in parvalbumin interneurons (using Dlx5/6-Cre or PV-Cre lines) reproduced the premature mortality and epilepsy phenotypes observed with global expression. In contrast, expression in excitatory neurons (Slc17a7-Cre) or in other interneuron subtypes (VIP-Cre or Sst-Cre) did not reproduce the lethal epilepsy phenotype. These results implicate dysfunction of PV-positive inhibitory interneurons as the primary driver of seizures and early death in this GoF model.
The study tested a targeted pharmacologic strategy by treating Scn1a-p.R1636Q mutant mice with the sodium channel blocker GS967. Treatment with GS967 markedly prolonged lifespan in the mutant animals. The reported therapeutic effect supports the concept that sodium channel blockade can mitigate disease severity in at least this preclinical GoF model.
This mouse model provides the first in vivo preclinical platform to study SCN1A GoF epilepsy. Key implications include:
The model may enable studies to distinguish cellular and molecular differences between SCN1A loss- versus gain-of-function disorders and to inform genotype-guided treatment development.
The report is presented as a preprint and has not undergone peer review. The source provides the principal experimental findings (global lethality, cell-type specificity implicating PV interneurons, and GS967-mediated lifespan extension) but does not detail all experimental methods, full datasets, electrophysiologic characterizations, dosing regimens, or long-term functional outcomes in the manuscript summary. Those details will need to be consulted in the full peer-reviewed publication when available.
Overall, the described Scn1a-flox(R1636Q) mouse is a novel preclinical model that links NaV1.1 gain-of-function in inhibitory interneurons to severe early-onset epilepsy and seizure-related mortality, and that demonstrates proof-of-concept pharmacologic rescue with a sodium channel blocker.